Urmila Sehrawat is a Postdoctoral Research Scholar at the Memorial Sloan Kettering Cancer Center. In her current role, she focuses on understanding mechanistic ways of targeting translation control in hematological malignancies such as Lymphoma and Acute Myeloid Leukemia. In 2021, She received her Ph.D. in Biochemistry at the Weizmann Institute of Science; her Ph.D. findings led to the discovery of novel translation initiation inhibitors. She has actively contributed to publishing several research articles in high-impact journals. Her areas of expertise include Cancer Biology, RNA Biology, Translation Control, and Protein Synthesis.
Urmila Sehrawat is a Postdoctoral Research Scholar at the Memorial Sloan Kettering Cancer Center. In her current role, she focuses on understanding mechanistic ways of targeting translation control in hematological malignancies such as Lymphoma and Acute Myeloid Leukemia. In 2021, She received her Ph.D. in Biochemistry at the Weizmann Institute of Science; her Ph.D. findings led to the discovery of novel translation initiation inhibitors. She has actively contributed to publishing several research articles in high-impact journals. Her areas of expertise include Cancer Biology, RNA Biology, Translation Control, and Protein Synthesis.